TriangleNCT00410761 · OUTCOME
Biochemical Response Carcinoembryonic Antigen (CEA)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Blood samples for analysis of CEA were taken at screening baseline (average of 0, 1, 4 and 8 hours), then every 4 weeks until discontinuation and 60 day follow up
What was measured
Best biochemical response was calculated from assessments at baseline and during treatment. Responders were those patients with a best biochemical response of CR or PR, confirmed by repeat assessments, which were to be performed no less than 4 weeks after the criteria for PR or CR were first met. CR and PR being defined according to level of CEA.
Groups in this outcome
Vandetanib 300 mg
Vandetanib (300 mg daily)
Placebo
Placebo daily
| Group | Source count |
|---|---|
| Vandetanib 300 mg | 231 |
| Placebo | 100 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Vandetanib 300 mg | 119 | Not reported | Not reported | Not reported | Not reported |
| Placebo | 2 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 119
- group Id
- OG001
- value
- 2
- denoms
- counts
- group Id
- OG000
- value
- 231
- group Id
- OG001
- value
- 100
- units
- Participants
- description
- Best biochemical response was calculated from assessments at baseline and during treatment. Responders were those patients with a best biochemical response of CR or PR, confirmed by repeat assessments, which were to be performed no less than 4 weeks after the criteria for PR or CR were first met. CR and PR being defined according to level of CEA.
- groups
- description
- Vandetanib (300 mg daily)
- id
- OG000
- title
- Vandetanib 300 mg
- description
- Placebo daily
- id
- OG001
- title
- Placebo
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- Blood samples for analysis of CEA were taken at screening baseline (average of 0, 1, 4 and 8 hours), then every 4 weeks until discontinuation and 60 day follow up
- title
- Biochemical Response Carcinoembryonic Antigen (CEA)
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice